GlassScriptPhysician profile
Jane J Choi
NPI 1891004768
$11,220.79
in general payments reported to CMS, 2019-2025
39 companies · $2,515 in 2025
The $2,515 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $780 · 2021: $1,626 · 2022: $1,845 · 2023: $1,817 · 2024: $2,032 · 2025: $2,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,193 · Education: $132 · Consulting Fee: $39.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,193.04 |
| Education | $132.34 |
| Consulting Fee | $39.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,999.61 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $1,511.81 | 2019-2025 | |
| Csl Behring | $1,041.04 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Glaxosmithkline, LLC. | $1,018.08 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $822.37 | 2021-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $777.39 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $509.53 | 2019-2025 | |
| Pfizer INC. | $454.68 | 2019-2025 | |
| Genentech USA, INC. | $311.56 | 2019-2025 | Xolair, Xofluza |
| Takeda Pharmaceuticals U.S.A., INC. | $300.90 | 2020-2024 | Cuvitru, Eohilia |
| Kaleo, INC. | $256.00 | 2019-2023 | Auvi-Q |
| Optinose US, INC. | $245.90 | 2020-2025 | |
| Octapharma USA, INC. | $222.42 | 2021-2023 | Cutaquig |
| Ars Pharmaceuticals Operations, INC. | $193.31 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $148.58 | 2019-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.